Craig C. Hopkinson - 18 Feb 2025 Form 4 Insider Report for Alkermes plc. (ALKS)

Role
EVP R&D, Chief Medical Officer
Signature
/s/ Stephanie Roche, attorney-in-fact for Craig C. Hopkinson
Issuer symbol
ALKS
Transactions as of
18 Feb 2025
Net transactions value
-$141,805
Form type
4
Filing time
20 Feb 2025, 17:13:46 UTC
Previous filing
14 Feb 2025
Next filing
25 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALKS Ordinary Shares Options Exercise +8,896 +15% 66,771 18 Feb 2025 Direct F1
transaction ALKS Ordinary Shares Tax liability $141,805 -3,950 -5.9% $35.90 62,821 18 Feb 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALKS Restricted Stock Unit Award Options Exercise -8,896 -50% 8,897 18 Feb 2025 Ordinary Shares 8,896 Direct F1, F2
transaction ALKS Employee Stock Option (Right to Buy) Award $0 +63,991 $0.000000 63,991 19 Feb 2025 Ordinary Shares 63,991 $35.84 Direct F3
transaction ALKS Restricted Stock Unit Award Award $0 +30,692 $0.000000 30,692 19 Feb 2025 Ordinary Shares 30,692 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one ordinary share.
F2 Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023.
F3 Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/19/2026.
F4 Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/19/2026.